
Tim McCutcheon
IN WHAT is still called Ovoca Bio, CEO (for the second time) Tim McCutcheon – who is also the largest shareholder with 22% – has shifted the focus of the failed biopharma business into, unsurprisingly, the mineral exploration business. What is clear is that this development will stimulate a jump in the market’s level of… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!